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Human colon adenocarcinomaA critical risk factor in colorectal carcinogenesis and tumor therapy is the resistance to the apoptotic effects of
different compounds from the intestinal lumen, among them butyrate (main regulator of colonic epithelium
homeostasis). Insensitivity to butyrate-induced apoptosis yields resistance to other agents, as bile acids or
chemotherapy drugs, allowing the selective growth of malignant cell subpopulations. Here we analyze bile
acid-induced apoptosis in a butyrate-resistant human colon adenocarcinoma cell line (BCS-TC2.BR2) to
determine the mechanisms that underlay the resistance to these agents in comparison with their parental
butyrate-sensitive BCS-TC2 cells. This study demonstrates that DCA and CDCA still induce apoptosis in
butyrate-resistant cells through increased ROS production by activation of membrane-associated enzymes
and subsequent triggering of the intrinsic mitochondrial apoptotic pathway. Although this mechanism is
similar to that described in butyrate-sensitive cells, cell viability is signiﬁcantly higher in resistant cells.
Moreover, butyrate-resistant cells show higher Bcl‐2 levels that confer resistance to bile acid-induced
apoptosis sequestering Bax and avoiding Bax-dependent pore formation in the mitochondria. We have
conﬁrmed that this resistance is reverted using the Bcl-2 inhibitor ABT-263, thus demonstrating that the
lower sensitivity of butyrate-resistant cells to the apoptotic effects of bile acids is mainly due to increased Bcl-2
levels.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
The homeostasis of the colonic epithelium is tightly regulated by
different compounds present in the intestinal lumen. Themost relevant is
butyrate, derived from the anaerobic fermentation of dietary ﬁber by the
colonic bacterial ﬂora. Butyrate not only constitutes the main energy
source for colonocytes but is also a well-known endogenous histone
deacetylase inhibitor. This activity leads to changes in the gene expression
proﬁle orchestrating the renewal process of the colonic epithelium [1,2].
The proliferation and differentiation programs followed by colonocytes
depend on the characteristic structure of the colon crypts and on the
accessibility of luminal compounds to the cells. Colonocytes present a
higher differentiation state at the top of the crypts whereas undiffer-
entiated stem cells are localized at the bottom [3]. The exposition to low
butyrate concentration at the bottom of the crypts is thought to stimulate
proliferation of stem cells [4] maintaining a low differentiation state. Inlic acid; DCA, deoxycholic acid;
ate; DMSO, dimethyl sulfoxide;
ed kinase; JNK, c-Jun N-terminal
ty-cysteine; PLA2, phospholipase
carbonyl-Val-Ala-Asp(O-methyl)
+34 91 394 4159.
rights reserved.contrast, cells at the top of the crypt are exposed to high concentrations of
butyrate, that activate their differentiation program ﬁnally triggering
apoptosis and allowing the renewal of the intestinalmucosa [5]. However,
if certain colon cells acquire resistance to butyrate or other luminal
compounds, theymay survive apoptosis and potentially progress towards
malignancy [6,7].
Bile acids are amphipathic molecules that allow lipids to be
absorbed in physiological conditions, but they have also been proposed
as potentially dangerous in individuals with different pathologies or
with a fat-rich diet, where their concentrations are elevated [8]. Bile
acids can promote DNA damage triggering apoptosis, as described in
hepatocytes and different colon-cancer cell lines [9,10]. Moreover, cells
with unrepaired DNA damage may accumulate mutations leading to
gastrointestinal cancer due to their resistance to apoptosis [7,11]. Thus,
it is essential to understand not only how bile acids exert their cytotoxic
activity, but also the molecular mechanisms responsible for the
acquisition of resistance to apoptosis. We have previously described
the induction of apoptosis by deoxycholic (DCA) and chenodeoxycholic
(CDCA) acids by oxidative stress in human colon adenocarcinoma BCS-
TC2 cells [12]. Activation of different membrane-associated enzymes
[mainly NAD(P)H oxidases] leads to an increase of reactive oxygen
species (ROS) that eventually triggers the mitochondrial apoptotic
pathway. The activation of caspase-3 by the apoptosome activates Bax
by degradation of Bcl-2, thus generating a feedback loop that ampliﬁes
the apoptotic signal.
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differentiated human colon adenocarcinoma [13]. These cells are non-
tumorigenic and sensitive to differentiation and apoptosis induced by
butyrate. Moreover, this agent alters their morphology, increases
protein biosynthesis and modiﬁes the gene expression proﬁle affecting
several genes involved in cell proliferation, differentiation and apopto-
sis [14,15]. On the other hand, BCS-TC2.BR2 cells were established by
continuous culture of BCS-TC2 cells in the presence of 2 mM butyrate
and selection of a subpopulation permanently resistant to butyrate-
induced apoptosis [16] and also to other types of stress including the
cytotoxic effect of bile acids [17,18]. In addition, these cells are
tumorigenic, show higher basal differentiation degree compared to
parental cells and butyrate still induces further differentiation without
signiﬁcant changes in cell proliferation.
Here we have studied the cytotoxic effect of bile acids in BCS-TC2.BR2
cells.Wehave observed that themechanismof apoptosis triggered by bile
acids in butyrate-resistant cells is similar to that observed in butyrate-
sensitive cells (oxidative stress). However, BCS-TC2.BR2 cells express
higher levels of antiapoptotic proteins, mainly Bcl-2, that prevent the
activation of Bax. Thus, resistant cells do not show the feedback loop
present in parental cells, increasing their survival to bile acid-induced
apoptosis.
2. Materials and methods
2.1. Materials
Bile acids (CA, CDCA and DCA), N-acetyl-cysteine (NAC), cisplatin,
N-benzyloxycarbonyl-Val-Ala-Asp(O-methyl) ﬂuoromethylketone
(Z-VAD-FMK), rhodamine-123, 2′,7′-dichloroﬂuorescein diacetate
(DCFH-DA), propidium iodide and protein G-Sepharose beads were
from Sigma (Alcobendas, Spain). The NAD(P)H oxidase activity in-
hibitors apocynin and diphenyleneiodonium (DPI) as well as the phos-
pholipase A2 (PLA2) inhibitor quinacrine were fromMerck (Darmstadt,
Germany). Speciﬁc inhibitors for p38-MAPK (SB203580), JNK-MAPK
(SP600125), and ERK1/2-MAPK (PD98059) were purchased from
Sigma. The Bcl-2 inhibitor ABT-263 (navitoclax) was from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Antibodies are described in the
corresponding ﬁgure legends. All other chemicals were of analytical
grade and were purchased from Sigma or Merck.
2.2. Cell culture, bile acid treatments and cell viability
The establishment and characterization of BCS-TC2 and BCS-TC2.BR2
cells have been previously described [13,16]. These cellswere cultured in
Dulbecco's modiﬁed Eagle's medium, containing 4.5 g/l glucose, and
supplemented with 5% heat-inactivated fetal calf serum, penicillin
(50 IU/ml), streptomycin (50 μg/ml) and glutamine (300 μg/ml). BCS-
TC2.BR2 cells were maintained in standard growth medium in the
presence of 2 mMbutyrate. Routinely, cells were cultured at 37 °C under
a humidiﬁed atmosphere of 5% CO2 and 95% air. The culturemediumwas
replaced every three days and cells were routinely weekly subcultured
by trypsinization.
Stock solutions of bile acids were prepared at 100 mM in dimethyl
sulfoxide (DMSO) and maintained at -20 °C. Aliquots were added to the
supplemented culture medium to obtain the appropriate ﬁnal concen-
tration of bile acid and at ﬁnal DMSO concentration of 0.5% (v/v). Cell
treatments were always carried out on subconﬂuent cultures. Cells were
seeded at 3–6×104 cells/cm2 in supplemented culture medium and
were allowed to attach and grow for 2 days before the addition of fresh
culture medium containing the corresponding bile acid. Cells were then
incubated under these conditions during the required periods of time.
Cell viability was determined using an adenosine triphosphate (ATP)-
bioluminescence assay (CellTiter-Glo, Promega, L'Hospitalet de Llobregat,
Spain). Luminiscence was measured in a Lumat LB 9507 luminometer
(Berthold, Germany).2.3. Flow cytometry analysis
For ﬂow cytometry, 106 cells resuspended in 10 mM Hepes, pH 7.4,
containing 150 mM NaCl, 5 mM KCl, 1 mM MgCl2 and 1.8 mM CaCl2,
were incubated for 15 min at room temperature in the presence of either
2 μg/ml annexin A5-FITC (obtained and labeled in our laboratory [19]) or
1 μg/ml rhodamine-123 in order to analyze reversion of membrane
asymmetry or changes in mitochondrial membrane potential, respec-
tively. Debris and clumpswere excluded bymonitoring forward and side
scattering parameters. To discern necrotic cells, 5 μg/ml propidium
iodide was added. Analyses were performed in a FACScan cytometer
(Becton-Dickinson, San Jose, CA), as previously reported [12].2.4. Fluorimetric determination of reactive oxygen species
Cells were seeded in 96-well plates and incubated for 2 h in the
presence of 500 μM DCA or CDCA followed by addition of 10 μM 2′,7′-
dichoroﬂuorescein diacetate (DCFH-DA) to quantify ROS generation.
After a 15 min incubation at 37 °C, oxidized DCFH ﬂuorescence was
measured in a Fluostar Optima (BMG Labtech, Offenburg, Germany).
In order to check the effect of NAD(P)H oxidases and PLA2 inhibitors
on ROS production, a 2 h preincubation with these inhibitors or with the
ROS scavenger NAC (N-acetyl-cysteine) was carried out; afterwards, the
mediumwas removed and cells were further incubated 2 hwith 500 μM
DCA before measuring ROS.2.5. Western blot analysis
Equal amounts of protein from cell homogenates were resolved by
SDS-PAGEafter heat denaturing in thepresence of 5%β-mercaptoethanol.
Proteins were transferred to nitrocellulose membranes and analyzed by
Western blot as described elsewhere [20]. Development was performed
using the “Amersham ECL Western blot system” (GE Healthcare,
Barcelona, Spain), and chemiluminescence was detected in a LAS-3000
mini image capture system from Fujiﬁlm. Densitometric analysis was
performed obtaining volumograms using Quantity One v4.6.6 (Bio-Rad).
Vinculin was used as protein loading control to normalize densitometric
determinations. Protein content was determined in quadruplicate
samples using the DC Protein Assay (Bio-Rad).2.6. Analysis of conformational changes in Bax
Cells (two dishes of 10 cmdiameter per sample) were left untreated
or subjected to a 1 h treatment with 500 μM DCA or CDCA [without or
after preincubation for 30 min with 50 μM Z-VAD-FMK (pan-caspase
inhibitor)], or 100 μM cisplatin (24 h), and then lysed in CHAPS lysis
buffer (1% CHAPS, 10 mMHEPES, pH 7.4, 150 mMNaCl, 20 μM leupeptin,
10 μg/ml aprotinin) to preserve the conformation of Bax, as previously
described [21]. For positive control, cells were lysed in Triton X-100-
containing buffer (1% Triton X-100, 20 mM Tris, pH 7.5, 150 mM NaCl,
1 mM EGTA, 10% glycerol, and protease inhibitors) to fully expose the
N-20 epitope. These lysates were either used as whole cell extracts or
for immunoprecipitation using protein G-Sepharose beads, as described
[12].2.7. Statistical analysis
The normal distribution of the data was determined by the
Kolmogorov–Smirnov test. ANOVA analyses and Student's t-tests
(two-tailed) were carried out using SigmaPlot v11.2 (Systat Software,
Erkrath, Germany). Statistical signiﬁcance was considered to be
achieved at the pb0.05 level.
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3.1. Effect of DCA and CDCA on cell viability and apoptosis
Cell viability was analyzed bymeasuring ATP content after treatment
with DCA and CDCA for different periods of time (Fig. 1A). No signiﬁcant
changes in cell viability were induced after treatment with cholic acid
(CA) up to 500 μM. DCA and CDCA reduced BCS-TC2 cell viability in a
time- and concentration-dependent manner, being the effect of CDCA
signiﬁcantly higher as revealed by ANOVA analyses (pb0.01 at the three
concentrations used). These analyses also revealed that the cytotoxic
effect of both bile acids was stronger in the parental cells compared toBCS-TC2.BR2BCS-TC2
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Fig. 1. Effect of bile acids on cell viability and apoptosis. (A) Cells were seeded into 96-well
plates at 1–2×104 cells/well in supplemented medium and were cultured for 2 days.
Afterwards,mediumwas removed and changed for fresh one containing the corresponding
bile acid and cell viability was analyzed after the indicated incubation time by measuring
ATP content using a luminometric assay as described in Materials and methods. Data are
normalized versus control cultures and represent mean values (±S.D.) from three
independent experiments with quadruplicate samples. ANOVA analyses reveal signiﬁcant
differences between DCA and CDCA treatments in BCS-TC2 cells at the three concentrations
used (only at 250 and 500 μM inBCS-TC2.BR2 cells) aswell as in comparisons between both
cell lines at the same concentrations of bile acids. (B) Apoptosis was determined after
treatment for 2 hwith 500 μMCA,DCA or CDCA. Cells were then collected by trypsinization
and stained with propidium iodide and FITC-annexin A5 and the percentage of apoptosis
was determined byﬂowcytometry from theannexinA5-positive cells. Data representmean
values (±S.D.) from three independent experiments (*, pb0.05 and **, pb0.01, comparison
between apoptosis in bile acid-treated cells vs. controls; ##, pb0.01, comparison between
the percentage of viable cells vs. controls).that observed in the resistant ones (pb0.05 at 100 μMDCA, and pb0.01
at higher DCA concentrations and all CDCA ones). Thus, after a 2 h
treatment, cell viability in BCS-TC2 cells decreased 34%with 500 μMDCA
and 50%with 500 μMCDCA, while BCS-TC2.BR2 cells suffered only a 19%
or 30% reduction in cell viability with 500 μMDCA or CDCA, respectively.
Moreover, the decreasewas observed at shorter incubation times in BCS-
TC2 cells (~15 min) compared to resistant cells (~30–60 min). ATP
depletion was parallel to an increase in the number of detached cells
(data not shown).
Induction of apoptosis was analyzed by measuring externalization of
phosphatidylserine in the plasmamembrane by ﬂow cytometry (Fig. 1B).
In BCS-TC2 cells, the percentage of apoptotic cells increased drastically
after CDCA treatment (41%) and to a lower extent with DCA (38%), being
this effect signiﬁcantly lower for BCS-TC2.BR2 cells (22% and 17%,
respectively; pb0.01 in both comparisons). The increase in apoptosis
was reﬂected in a decrease in the percentage of viable cells that was less
signiﬁcant in BCS-TC2.BR2 cells.
3.2. Bile acid-induced ROS generation and perturbations in mitochondrial
membrane potential
Wehave previously described that DCA and CDCA trigger the intrinsic
mitochondrial apoptotic pathway in BCS-TC2 cells through an initial
oxidative stress, as a consequence of the activation of several membrane-
associated enzymes, that induces mitochondrial pertubations [12]. Thus,
in order to verify if these mechanisms also take place after bile acid
treatment in butyrate-resistant cells, we have analyzed ROS production in
BCS-TC2.BR2 cells and the effect of NAC as well as speciﬁc inhibitors of
NAD(P)H oxidases (apocynin andDPI) and PLA2 (quinacrine) in both ROS
(Fig. 2A) and ATP levels (Fig. 2B). Preincubation with the inhibitors alone
did not signiﬁcantly alter (p>0.05) ROS or ATP levels (data not shown).
Incubation of BCS-TC2.BR2 cells with 500 μM DCA or CDCA for 2 h
induced an increase in ROS production (slightly higher for CDCA) that
was not detected in the presence of NAC. Interestingly, apocynin, DPI and
quinacrine also blocked ROS generation, which was reﬂected in a
protection against ATP depletion.
Alterations in themitochondrialmembrane potential in both cell lines
after a 2 h treatment with 500 μM DCA or CDCA using rhodamine-123
were also evaluated (Fig. 2C). CDCA induced a signiﬁcant decrease in the
mitochondrialmembrane potential, whichwas also observed to a lower
extentwith DCA; BCS-TC2 cells clearly showed the appearance of a new
cell population whereas only a slight increase in this population was
detected in resistant cells.
3.3. Apoptosis-related proteins and activation of Bax after treatment with
bile acids
Caspase activation in BCS-TC2.BR2 cells was analyzed by Western
blot after treatmentwith DCA and CDCA using butyrate-sensitive cells as
control (Fig. 3A). In BCS-TC2 cells CDCA triggered the activation of
caspase-9 with subsequent activation of caspase-3 (both caspases show
around 76% proteolytically activated fragments) and cleavage of PARP
(close to 100% cleavage). Regarding BCS-TC2.BR2 cells, activation of both
caspases and PARP cleavage was also observed, but only at the highest
concentration of both bile acids, being this effect clearly lower than in the
parental cells. In resistant cells, 500 μM DCA induced 27% and 20%
proteolytic activation of caspases-9 and ‐3, respectively, and 25% PARP
cleavage, whereas 500 μMCDCA induced higher caspase activation (39%
and 27%, respectively) and PARP cleavage (54%). No signiﬁcant changes
were observed in the protein levels of the transcription factor NF-κB
whereas a decrease was detected in p53 in BCS-TC2.BR2 extracts (36% at
500 μM DCA or CDCA). BCS-TC2 cells showed lower basal expression of
p53 (~60%) with a 30% decrease after CDCA treatment (Table 1).
Concerning the proapoptotic members of the Bcl-2 protein family,
we have not detected signiﬁcant changes in Bax levels (Fig. 3A). Bid
levels decreased after treatment with 500 μM CDCA in both cell lines
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Fig. 2. Inﬂuence of inhibitors of ROS production in BCS-TC2.BR2 cells. Analysis of
mitochondrial membrane potential after treatment with bile acids. (A) ROS production
was determined by a ﬂuorimetric assaymeasuring DCFH oxidation on 96-well plates after
a 2 h pretreatment of exponentially growing BCS-TC2.BR2 cells in the absence or in the
presence of 20 mMNAC, 100 μMapocynin, 50 μMDPI or 5 μMquinacrine (concentrations
with maximum inhibitory activity without inducing cytotoxicity), followed by a further
2 h treatment with 500 μM DCA or CDCA. Control cultures containing only vehicle were
used to normalize DCFH ﬂuorescence. (B) Viability was determined by measuring ATP
content in parallel cultures to those in (A) and normalized versus control cultures. Data in
(A) and (B) represent mean values (±S.D.) from two independent experiments with
quadruplicate samples (**, pb0.01; comparisons vs. controls with neither inhibitors nor
bile acid treatment). (C) Mitochondrial membrane potential was analyzed after
incubation with 500 μM DCA or CDCA for 2 h. After addition of rhodamine-123, cells
were analyzed by ﬂow cytometry. Representative histograms and total MFIs from three
independent experiments are shown.
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fragment only faintly appeared in the parental cells. This is probably due
to an unspeciﬁc cleavage by activated effector caspases, as we have not
detected caspase-8 activation. Among the three Bim isoforms, we have
not observed changes in the extra-long and long isoforms in BCS-TC2.BR2
cells after bile acid treatment, although there was a 35% decrease in the
extra-long isoform in BCS-TC2 cells after CDCA treatment (pb0.01). The
short isoform showed a small gradual increase in BCS-TC2.BR2 cells after
DCA treatment (~1.4-fold at 500 μM; pb0.05) whereas a ~30% decrease
was observedwith 500 μMCDCA (pb0.01) in both butyrate resistant and
sensitive cells (Table 1).We also analyzed the antiapoptotic members of the Bcl-2 family. No
signiﬁcant variations were detected in Bcl-xL protein levels. However, a
different behavior between both cell lines was observed in Bcl-2 and, to a
lower extent, in Mcl-1. Parental cells showed lower Mcl-1 basal protein
levels compared to resistant cells (1.23-fold decrease; pb0.05) with a
reduction of 35% after CDCA treatment (pb0.01) thatwas not observed in
BCS-TC2.BR2 cells (Table 1). More evident were the differences between
basal protein levels of Bcl-2, that were quite higher in the resistant cells
(3.7-fold; pb0.01) compared to the parental ones. Bile acid treatments
did not alter these levels in BCS-TC2.BR2 cells, while induced a severe
decrease in the parental cells (~70%; pb0.01).
Taking into account the differences in the protein levels of
antiapoptotic members of the Bcl-2 family, we checked total levels and
activation of Bax in BCS-TC2.BR2 cells in different conditions (Fig. 3B).
Bax activation was observed in the positive control using cisplatin or in
the lysate obtained in the presence of Triton X-100, but not after DCA
Table 1
Densitometric analysis and statistics corresponding to Western blots from Fig.3A.
p53/Vin (n=5) Bid(a)/Vin (n=4) Bim EL/Vin (n=4) Bim L/Vin (n=4) Bim S/Vin (n=4) Bcl-2/Vin (n=7) Mcl-1/Vin (n=5)
BCS-TC2.BR2
Control 1.00±0.10 1.00±0.09 1.00±0.10 1.00±0.09 1.00±0.07 1.00±0.06 1.00±0.08
DCA 100 μM 0.75±0.13* 0.94±0.09 0.97±0.07 1.10±0.12 1.07±0.12 0.93±0.07 0.99±0.09
DCA 250 μM 0.64±0.09** 1.01±13 0.98±0.08 0.94±0.11 1.22±0.08* 1.03±0.07 0.89±0.09
DCA 500 μM 0.64±0.12** 1.00±0.09 1.03±0.09 0.97±0.09 1.38±0.13* 0.94±0.08 1.21±0.12
CDCA 100 μM 0.81±0.12 1.22±0.12 1.10±0.11 0.97±0.11 0.94±0.11 1.07±0.09 1.05±0.13
CDCA 250 μM 0.69±0.13** 0.82±0.09* 0.93±0.09 0.81±0.13 0.67±0.09** 0.89±0.10 0.97±0.08
CDCA 500 μM 0.64±0.12** 0.56±0.08** 0.96±0.08 0.92±0.12 0.72±0.10** 1.01±0.08 1.12±0.09
BCS-TC2
Control 0.60±0.08** 0.84±0.09* 0.77±0.08* 0.97±0.09 0.77±0.09* 0.27±0.05** 0.81±0.08*
(1.00±0.13) (1.00±0.11) (1.00±0.10) (1.00±0.09) (1.00±0.12) (1.00±0.19) (1.00±0.10)
CDCA 500 μM 0.42±0.08)** 0.62±0.12** 0.50±0.10** 0.85±0.13 0.51±0.07** 0.07±0.03** 0.53±0.08**
(0.70±0.19)# (0.73±0.19)# (0.64±0.20)## (0.88±0.15) (0.66±0.14)## (0.26±0.43)## (0.65±0.15)##
Data correspond to mean values (±SD) of the normalized densitometric analysis of the intensity of the bands from 4 to 7 blots from independent experiments. They are expressed
in arbitrary units with a value of one for control BCS-TC2.BR2 cells (or control BCS-TC2 cells in parenthesis). Asterisks indicate p values corresponding to the comparison of mean
values with those obtained from the corresponding controls (*pb0.05 and **pb0.01, comparisons vs. BCS-TC2.BR2 controls or #pb0.05, and ##pb0.01 vs. BCS-TC2 controls). NF-κB,
total Bax and Bcl-xL expression levels did not show any signiﬁcant variations between BCS-TC2.BR2 and their parental cells, as well as with bile acid treatments. (a) tBid fragment
was only detected in BCS-TC2 cells treated with 500 μM CDCA.
2205J.I. Barrasa et al. / Biochimica et Biophysica Acta 1823 (2012) 2201–2209treatment; only a slight activation was detected after CDCA treatment
which was abolished by preincubation with the pan-caspase inhibitor
Z-VAD-FMK, as we have also previously observed in BCS-TC2 cells [12].
On the other hand, total levels of Bax and Bcl-2 remained mainly
unaltered with the different treatments.
3.4. Inhibition of Bcl-2 activity by ABT-263
Considering that one of the most interesting differences between
parental and resistant cells was the disparity in Bcl-2 protein levels, we
ﬁrst analyzed the effect of the Bcl-2 inhibitor ABT-263 in the cytotoxicity
of bile acids in both cell lines (Fig. 4A). ABT-263 alone did not signiﬁcantly
modify cell viability. On the other hand, the combined treatmentwith bile
acids and ABT-263 produced a synergistic effect in bile acid-dependent
ATP depletion at any of the evaluated concentrations. BCS-TC2.BR2 cells
were more affected by Bcl-2 inhibition with an almost complete loss of
resistance to bile acids showing ATP levels similar to those in butyrate-
sensitive cells.
As Bcl-2 exerts its antiapoptotic activity by blocking the oligomeriza-
tion of Bax, we checked if the combined treatment with bile acids andFig. 3. Expression of apoptosis-related proteins and Bax activation in BCS-TC2.BR2 cells
treated with DCA or CDCA. (A) Protein extracts were obtained by solubilization of the
monolayers in 10 mM Tris, pH 8.0, containing 140 mM NaCl, 2% (v/v) Triton X-100 and
protease and phosphatase inhibitors (1 mM PMSF, 1 μg/ml aprotinin, 1 nM pepstatin A,
1 μg/ml leupeptin, 1 nM Na3VO4, 1 nM NaF, 1 nM β-glycerophosphate and 1 mM
dithiothreitol). Western blots showing activation of caspases-9 and ‐3 (arrows show
fragments corresponding to proteolytic activation of pro-caspases-9 and ‐3), cleavage
of PARP, and levels of transcription factors NF-κB and p53, and several pro- and anti-
apoptotic proteins. Samples correspond to total cell extracts obtained after a 2 h
treatment of BCS-TC2.BR2 cells with different concentrations of DCA or CDCA, and BCS-
TC2 cells in the presence or in the absence of 500 μM CDCA. (B) Activation of Bax was
detected by immunoprecipitation of activated Bax using the N-20 polyclonal antibody
as described in Materials and methods. Cells were incubated with 500 μMDCA or CDCA
for 2 h with or without a 30 min preincubation with 50 μM Z-VAD-FMK (+Z-VAD).
Cisplatin incubation (CisPt; 100 μM, 24 h) was also carried out as a control of apoptosis.
Triton extraction was used as control of active-Bax immunoprecipitation due to the
exposure of the epitope recognized by the N-20 antibody with this detergent. Total Bax
and Bcl-2 were detected by Western blot of whole cell extracts. Vinculin levels are
shown as protein loading controls and were used to normalize densitometric
determinations. Blots from (A) and (B) are representative of three to six different
experiments. All blots were analyzed and numbers in (B) indicate mean values of the
densitometric analyses. The Baxactive/Baxtotal ratio was referred to the value obtained
after Triton extraction; total Bax and Bcl-2 were referred to control BCS-TC2.BR2 values
(*, pb0.05; **, pb0.01). Antibodies used: mouse monoclonal antibodies against human
p53 (Ab-6, clone DO-1, Thermo Scientiﬁc, Alcobendas, Spain), poly(ADP-ribose)
polymerase (PARP, Labclinics, Barcelona, Spain), vinculin (hVIN1, Sigma) and Bcl-2
(Santa Cruz Biotechnology); rabbit polyclonal antibodies against NF-κB (p50, H-119),
activated Bax (N-20) (both from Santa Cruz Biotechnology), Mcl-1, Bcl-xL, Bim, Bid,
and caspases-3 and -9 (from Cell Signaling, Danvers, MA, USA).ABT-263 turned into an increased Bax activation (Fig. 4B). Incubation
with ABT-263 alone promoted a slight activation of Bax in both cell lines
without changes in Bax or Bcl-2 total protein levels. CDCA treatment
alone yielded a signiﬁcant activation of Bax together with a strong
decrease in Bcl-2 levels in parental cells. Under these conditions, Bax
activation inBCS-TC2.BR2 cellswas almost undetectablewith only a slight
decrease in Bcl-2 levels. Interestingly, combined treatment with ABT-263
and CDCA showed a synergistic effect that turned into an increased Bax
activation in both cell lines (3.7- and13-fold in BCS-TC2 andBCS-TC2.BR2,
respectively; pb0.01) without signiﬁcant changes in Bcl-2 levels.
To conﬁrm that Bax activation after ABT-263 treatment contributes to
mitochondrial depolarization, we analyzed loss of mitochondrial mem-
brane potential byﬂow cytometry using rhodamine-123 in both cell lines.
No signiﬁcant changeswere detected in both cell lines after preincubation
with ABT-263 alone or in BCS-TC2 cells treatedwith 500 μMDCAor CDCA
in combination with ABT-263 (data not shown). However, co-treatment
of butyrate resistant cells with bile acids and ABT-263 promotes a
signiﬁcant increase in the cell population with a reduced mitochondrial
membrane potential (Fig. 4C).
3.5. Effect of bile acids in cell signaling pathways
We analyzed the effects of bile acid treatments in the activation of
several kinases by Western blot (Fig. 5A). Regarding MAPKs, we did not
ﬁnd signiﬁcant changes in total levels of ERK1/2 and p38. JNK levelswere
very low in both cell lines, but resistant cells showed higher expression
than parental cells with a reduction after DCA and CDCA treatments. On
the other hand, we detected an increase in phosphorylation of ERK1/2,
p38 and JNK in both cell lines. In BCS-TC2.BR2, phosho-ERK1/2 increased
3.5- and 4-fold upon treatment with 500 μM DCA and 250 μM CDCA,
respectively; phospho-p38 increased 2.4-fold at 500 μM DCA and CDCA
(Fig. 5B). Interestingly, parental cells showed an increased ERK1/2 basal
phosphorylated state (3.4-fold; pb0.01) compared to resistant cells;
500 μM CDCA also induced an increase in its phosphorylation level,
although to a lower extent than in butyrate-resistant cells (1.8-fold;
pb0.01). However, cell viability studies in the combined presence of DCA
and CDCA together with speciﬁc MAPK inhibitors (SB203580, PD98059
and SP600125; p38, ERK1/2 and JNK inhibitors, respectively) did not
reveal any signiﬁcant differences with the corresponding treatments in
the absence of the inhibitors (data not shown).
Akt presented a different behavior upon incubation with bile acids.
Whereas no signiﬁcant differences were observed in Akt total levels in
BCS-TC2.BR2 cells, a decrease around 50% (pb0.01) was detected in
parental cells after CDCA treatment (Fig. 5A). In addition, and opposite to
MAPKs, bile acid promoted a reduction in Akt phosphorylation in
Fig. 4. Effect of the Bcl-2 inhibitor ABT-263 on cell viability, Bax activation and
mitochondrial membrane potential after treatment with bile acids. (A) Cell viability was
determinedmeasuring ATP content after a 2 h preincubation of BCS-TC2 and BCS-TC2.BR2
cultureswith orwithout 3 μMABT-263 followed by a further 2 h exposure to the indicated
concentrations of DCA or CDCA. Data are normalized versus control cultures containing
only vehicle and represent mean values (±S.D.) from three independent experiments
with quadruplicate samples. ANOVA analysis reveals signiﬁcant differences in the DCA
and CDCA concentration dependent effect between BCS-TC2 and BCS-TC2.BR2 cells in the
absence of ABT-263 inhibitor, but there are no signiﬁcant differences when cells were
pretreated with ABT-263. (B) Activation of Bax was detected by immunoprepitation as
described in Fig. 3. Cells were preincubated with ABT-263 as indicated in (A) and further
treatedwith orwithout 500 μMCDCA for additional 2 h. Total Bax and Bcl-2were detected
by Western blot of whole cell extracts; vinculin levels are shown as protein loading
controls and were used to normalize densitometric determinations. Blots are represen-
tative of four different experiments; all blots were analyzed and numbers indicate mean
values of the densitometric analyses. An arbitrary value of 1 was assigned to the highest
Baxactive/Baxtotal ratio (BCS-TC2 cells treated with 500 μM CDCA); for total Bax and Bcl-2,
valueswere normalized against the expression in control BCS-TC2.BR2 cells in the absence
of ABT-263 (**, pb0.01). Antibodies used are indicated in Fig. 3. (C) Mitochondrial
membrane potential was analyzed in BCS-TC2.BR2 cells after preincubation with (black
histograms) or without ABT-263 (gray histograms) followed by incubation with 500 μM
DCA or CDCA for 2 h. After addition of rhodamine-123, cells were analyzed by ﬂow
cytometry. Representative histograms and total MFIs from two independent experiments
are shown.
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Fig. 5. Effect of bile acids in cell signaling pathways. (A) Western blots showing total and
phosphorylated levels of ERK1/2, p38, JNK and Akt are shown. Samples correspond to
whole cell extracts obtained after a 2 h treatment of BCS-TC2.BR2 cells with different
concentrations of DCA and CDCA, and BCS-TC2 cells in the presence or in the absence of
500 μM CDCA. Vinculin levels are shown as protein loading controls and were used to
normalize densitometric determinations. Blots are representative of four different
experiments. (B) Densitometric analysis of the phosphorylation degree of ERK1/2, p38
and Akt obtained fromWestern blots in (A). The phosphorylation degrees are normalized
versus the corresponding values from control cultures of BCS-TC2.BR2 and BCS-TC2 cells.
Data correspond to mean values (±S.D.) from unsaturated blots from four different
experiments (*, pb0.05 and **, pb0.01; comparisons vs. corresponding controls).
Antibodies used: rabbit polyclonal antibodies against p38-MAPK, ERK1/2 (p44/42),
SAPK/JNK, Akt, phospho-p38 (Thr180/Tyr182), phospho-ERK1/2 (Thr202/Tyr204),
phospho-SAPK/JNK (Thr183/Tyr185) and phospho-Akt (Ser473; 193H12) (all from Cell
Signaling).
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(Fig. 5B).
4. Discussion
Colorectal cancer is one of the most common causes of cancer death
in theworld, withmore than 600,000 annual deaths [22]. Understanding
how cells are able to acquire chemoresistance to different compounds is
not only essential to improve our knowledge about the induction and
development of tumors, but also for the design of new therapeutic
strategies. On this idea, the establishment of cell lines with acquired
2207J.I. Barrasa et al. / Biochimica et Biophysica Acta 1823 (2012) 2201–2209resistance to colonic luminal agents involved in the renewal of the colon
epithelium yields an essential tool for these studies. Regretfully, only a
few models have been developed for butyrate [16,23,24] and DCA [25]
resistance. Here we take advantage of a cell system in which butyrate-
sensitive and resistant cells can be compared to dissect their molecular
differences regarding bile acid-triggered apoptosis and the signaling
pathways involved. BCS-TC2.BR2 cells are not only resistant to the
apoptotic effects of butyrate but also to other different stresses such as
heat shock or glucose deprivation [17].Moreover, butyrate-resistant cells
also show an enhanced survival to the cytotoxic effects of bile acids
compared to the parental cell line [18]. We have previously described
that bile acids trigger the intrinsic apoptotic pathway in BCS-TC2
butyrate-sensitive cells via oxidative stress by activation of membrane-
associated NAD(P)H oxidases and PLA2 [12]. The former directly
generates superoxide, and the latter releases arachidonic acid, which is
substrate of cyclooxygenase and lipoxygenase to release ROS through
the partial reduction ofmolecular oxygen that accompanies formation of
prostaglandins and leukotrienes.
We have analyzed the cytotoxic effects of DCA and CDCA at a short
treatment time (2 h) in both butyrate-sensitive and resistant cells.
BCS-TC2.BR2 cells are still sensitive to bile acid-induced cytotoxicity
although to a signiﬁcantly lower extent than BCS-TC2 cells. Apoptosis is
also triggered by an enhancement in ROS production, greater with CDCA
probably due to its higher hydrophobicity, which ﬁnally leads to an
impairment of mitochondrial functionality followed by caspase activa-
tion. This fact has been conﬁrmed using speciﬁc inhibitors for NAD(P)H
oxidases and PLA2, which reduced intracellular ROS levels with a
subsequent recovery in cell viability. Taking into account that bile acids
trigger apoptosis in both cell lines through a similar mechanism, the
question that arises is: what is the difference between butyrate-sensitive
and resistant cells, which confers the enhanced survival of the latter to
bile acid-induced apoptosis?
We have previously described that bile acid-induced apoptosis in
BCS-TC2 cells eventually leads to the activation of effector caspase-3 via
apoptosome,which promotes the degradation of Bcl-2, thus releasing Bax
from the Bcl-2/Bax complexes. Then Bax is able to oligomerize and form
mitochondrial pores that enhance the release of proapoptotic factors to
the cytosol, acting as a proapoptotic feedback loop (Fig. 6A) [12]. Here, we
have conﬁrmed by Western blot the activation of caspases 9 and 3 after
bile acid treatment not only in BCS-TC2 cells but also in BCS-TC2.BR2 cells,
being this effect quite stronger in the former as expected. The decreased
caspase activity in BCS-TC2.BR2 cells is reﬂected in a lower cleavage of
apoptotic targets, as PARP. Regarding p53 degradation, not only caspases
may cleave it, but it has also been described that bile acidsmay activate it
proteasomal degradation via stimulation of ERK signaling pathway [26].
These observations are in good agreement with our results showing an
increased p53 degradation in both cell lines togetherwith an activation of
ERK. Although the decrease in p53 levels is similar in both cell lines, the
contribution of caspases to this effect is higher in BCS-TC2 cells. It isworth
mentioning that p53 fragments arising from caspase degradation may
contribute to an enhancement of apoptosis via mitochondrial membrane
depolarization [27]. Thus, the reduced caspase-dependent p53 cleavage in
BCS-TC2.BR2 cells could contribute to their enhanced resistance to bile
acid-induced apoptosis.
Regarding proapoptotic proteins, levels of Bax remain mainly
unaltered after bile acid treatments suggesting that the apoptotic effects
of this protein occur through modulation of its activity. On the other
hand, Bim showed modiﬁcations with bile acid treatments in both cell
lines, mainly affecting the most potent apoptosis-inducing isoform, Bim
S. Interestingly, whereas DCA induces a 1.4-fold increase in this isoform
in BCS-TC2.BR2 cells, CDCA promotes a ~30% decrease in its levels. This
apparent contradiction could be explained taking into account that it has
been described that caspase-3 negatively regulates Bim expression by
stimulating its degradation [28]. Thus, although bile acids may induce
Bim expression, the higher caspase-3 activation detected in CDCA- vs.
DCA-treated cells may counteract this effect.More interestingly, we have observed clear differences in protein
levels of different antiapoptotic members of the Bcl-2 family
between butyrate-sensitive and resistant cells. Thus, while Bcl-xL
seems to be unaltered after treatments and shows equivalent levels
between both cell lines, Bcl-2, and to a lower extent Mcl-1, are
overexpressed in BCS-TC2.BR2 cells and are not modiﬁed by bile acid
treatments. On the other hand, BCS-TC2 cells show a clear reduction
in Bcl-2 levels after CDCA treatment, as we have previously described
[12], together with a slight decrease in Mcl-1. These results could
explain the apoptosis resistance of BCS-TC2.BR2 cells due to high
levels of the antiapoptotic protein Bcl-2, which sequesters Bax
avoiding its oligomerization in the mitochondrial membrane. In this
regard, Bax activation assays conﬁrmed that resistant cells show only
a slight Bax activation after CDCA treatment (not detected with
DCA), compared to the strong activation observed in sensitive cells.
To conﬁrm this hypothesis, we decided to use the Bcl-2 inhibitor
ABT-263, a small molecule that mimetizes the BH3 domain of Bcl-2
protein family members. Thus, it is able to bind to the groove of different
antiapoptotic members, blocking their ability to interact with their
physiological partners. ABT-263 shows high afﬁnity towards Bcl-2, Bcl-xL
and Bcl-w, but low afﬁnity for Mcl-1 [29]. Bax activation assays in the
presence of ABT-263 conﬁrmed that Bcl-2 is responsible for the low Bax
activation levels in BCS-TC2.BR2 cells, as we observed a synergistic effect
between CDCA and ABT-263. This effect correlates with a signiﬁcant
decrease in mitochondrial membrane potential followed by a reduction
in cell viability after treatment of butyrate resistant cells with bile acids
in combination with ABT-263. Moreover, under these conditions,
almost no differences were found in cell viability between BCS-TC2
andBCS-TC2.BR2 cells. Thus, the correlation between inhibition of Bcl-2,
increased Bax activation and decreased viability strongly suggests that
the high levels of Bcl-2 are responsible for the resistance against bile
acid-induced apoptosis in BCS-TC2.BR2 cells (Fig. 6B). In this regard, it
has been previously described that DCA-resistant cells derived from the
HCT-116 cells overexpress Bcl-2 [25], and that overexpression of Bcl-2
by transfection of HCT-116 cells suppresses DCA-induced apoptosis
[30].
We have also observed activation of different signaling pathways
after DCA and CDCA treatments: increased phosphorylation of ERK1/2,
p38 and JNK. The activation of these MAPKs could be explained as a
defensive response of the cell, trying to overcome the apoptotic effects
of these agents. In fact, the strongest activation of these kinases is
achieved with those treatments that induce the highest cytotoxicity. In
addition, resistant cells exhibit a stronger survival response. Stimulation
of these MAPK pathways after bile acid treatment has been previously
observed in different colon cancer cell lines. Thus, DCA induces ERK
activation in HCT-116, Caco-2, H508 and SNU-C4 cells through different
mechanisms [31,32]. Moreover, bile acids induce an increase in ROS
production in Caco-2 cells via activation of PLA2, NADH dehydrogenase
and xanthine oxidase that, in turn, promote the phosphorylation of p38
and ERK1/2 [33]. Activation of p38 and ERK in DCA-treated HCT-116
cells has been suggested as a prosurvival signal against the proapoptotic
effects of bile acids [34]. A similar protective effect has been described
for JNK activation, but mainly in hepatocytes, via regulation of several
apoptosis-related proteins [35]. However, the resistance against bile
acid-induced apoptosis in BCS-TC2.BR2 cells seems to be more
dependent on Bcl-2 overexpression as speciﬁc inhibition of MAPK
signaling pathways did not signiﬁcantly affect cell viability.
Regarding Akt, we have observed a reduction in the phosphorylation
state after bile acid treatments that mainly affected butyrate-resistant
cells, whereas in BCS-TC2 cells a decrease in total Akt levelswas observed.
Similar results have been recently observed in several cell lines after
induction of oxidative stress by different agents; Akt phosphorylation
decreases contributing to apoptosis induction [36,37]. Even more,
ROS-induced suppression of Akt pathway may be accompanied by
MAPKs activation in a similar pattern to that observed in our cell
system [38,39].
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Fig. 6. Proposed mechanism of resistance to bile acid-induced apoptosis in BCS-TC2.BR2
cells. As we have previously described, the main triggering factor for DCA- and CDCA-
induced apoptosis in BCS-TC2 cells is ROS production by activation of membrane
associated enzymes NAD(P)H oxidases and PLA2 (A). ROS induce the formation of the
mitochondrial transition pore (MTP), initiating the intrinsic apoptotic pathway. Activation
of effector caspase-3by the apoptosome leads to degradation of Bcl-2, thus allowingBax to
form additional pores in the mitochondrial membrane and amplifying the apoptotic
response. Resistance to bile acid-induced apoptosis in BCS-TC2.BR2 cells (B) is the
consequence of their higher basal levels of the antiapoptotic protein Bcl-2 compared to
BCS-TC2 cells. Although caspase-3 is active after bile acid treatments in resistant cells, its
activity is not enough to cleave Bcl-2 to the same extent than that achieved in butyrate-
sensitive cells. Therefore, Bax remains sequestered and the apoptotic feedback loop is
blocked.
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Taking into account all these results, we suggest that BCS-TC2.BR2
cells show resistance to bile acid-induced apoptosis mainly due to an
overexpression of Bcl-2 that overcomes the pro-apoptotic feedback loop
observed in BCS-TC2 cells, although the presence of other mechanisms
cannot be discarded. After activation of the intrinsic apoptotic programby
oxidative stress, caspase-3 is not able to degrade enough Bcl-2 protein to
allow the release of Bax, the formation of Bax-dependent pores in the
mitochondrial membrane and the subsequent release of proapoptotic
factors. Here we demonstrate that resistance can be reverted in vitro by
the use of the Bcl-2 inhibitor ABT-263. This suggests that acquisition of
resistance to several compounds used in colorectal carcinoma treatments,
such as the clinically usedderivatives of butyrate or otherHDAC inhibitors
[40], could be potentially reverted by oral co-administrationwith the Bcl-
2 inhibitor ABT-263 in tumors where elevated levels of this protein are
detected.
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